Aurobindo Pharma Ltd. reported a 32.5% YoY rise in consolidated net profit to approximately Rs.1,124 crore for the second quarter of FY27, compared with Rs.848 crore in the corresponding quarter last year. The company also reported record revenue from operations during the quarter, supported by stronger performance across its pharmaceutical formulations and active pharmaceutical ingredients (API) businesses.
The company’s performance reflects continued demand across its domestic and international markets. Its formulations business and API operations remain important contributors to its overall revenue, while product launches and regulatory approvals are key factors influencing its growth outlook.
The quarterly results will be monitored by investors for further details on operating margins, geographical performance and the sustainability of growth across its major business segments.
